How do HIV drugs work?

The development of drugs capable of attacking HIV at different points of its life cycle has completely transformed HIV treatment, with infected patients being able to live nearly as long as healthy individuals

The goal of HIV treatment is to reduce the amount of virus (viral load) in the body, and to increase the number of CD4 cells in order to sustain a strong immune system against infectious microorganisms.

Goal of HIV therapy: lower viral load and raise CD4 cell counts
Figure 1. The objective of HIV therapy is to reduce viral load and to increase CD4 counts to normal levels

Effective management of HIV infection is possible with HAART (highly active antiretroviral therapy), in which a combination of several drugs is used to prevent HIV from replicating, reducing the risk of disease transmission and restoring immune system function.

But why do we need to use so many drugs?

This is because HIV mutates so rapidly that if only one drug was given, the virus would become resistant to the treatment super quickly, allowing the disease to potentially progress into AIDS. So by using several drug classes, the virus would have to undergo multiple mutations to develop resistance; and this is very unlikely to happen.

Currently, we have 4 drug classes that inhibit HIV replication at different points of its life cycle. They are:

· Fusion and chemokine receptor inhibitors

· Reverse transcriptase inhibitors

· Integrase inhibitors

· Protease inhibitors

When HIV infects an individual, the virus circulates in the bloodstream and uses CD4 T helper cells to replicate. In order to achieve this, the virus employs several highly specific proteins and enzymes; many of which can be targeted with HIV drugs.

So now, let’s dive into the HIV life cycle and examine how the different drugs attack the virus.

In order to gain access into the cell, HIV uses the membrane proteins (gp41 and gp120) to interact with the receptor CD4 and the co-receptor CCR5 on the surface of T helper cells. When this occurs, HIV is able to deceive the cell and release its genetic content.

[Fusion and chemokine receptor inhibitors block the CD4 receptor and CCR5 co-receptors, preventing the virus from entering into T helper cells]

Fusion and chemokine receptor inhibitors blocking HIV entry into CD4 cells
Figure 2. Chemokine/fusion inhibitors block the entry of HIV into CD4 cells

Once HIV has entered the cell, the first thing it does is to modify its genetic material using the enzyme reverse transcriptase.

Do you know why it does this?

You see, our genetic material is found in chromosomes as double stranded DNA, whereas HIV has its genetic material in the form of single stranded RNA. So, by using reverse transcriptase, HIV converts its RNA into complementary DNA.

[Reverse transcriptase inhibitors block the actions of reverse transcriptase and prevent the virus from changing its genetic material into DNA]

After converting its genetic material into double stranded DNA, HIV uses an enzyme known as integrase.

As you can probably guess from its name, integrase inserts and integrates the viral DNA into the host cell genome. It is an impressive enzyme that zips a hole into our DNA, and then adds the viral genetic code into our cells.

Unfortunately, CD4 cells don’t realise when that they are hijacked; meaning that when they process their DNA to make proteins, they will actually produce HIV viral proteins!

[Integrase strand transfer inhibitors inhibit the actions of the integrase enzyme, blocking the integration of viral DNA into the genome of CD4 cells]

Integrase inhibitors preventing HIV DNA from integrating into CD4 cell DNA
Figure 3. Integrase inhibitors prevent HIV from inserting its DNA into the genetic chain of CD4 cells

Even after the replication machinery of CD4 cells makes viral particles, HIV is still not ready and must assemble itself using yet another enzyme: protease.

Protease is essentially an organiser that gathers all the viral particles hanging around the cell, assembling a full mature HIV virus that is then ready to attack more CD4 cells.

[Protease inhibitors deactivate viral protease and halt the maturation of HIV. With these drugs, viral particles are still produced, but they are completely harmless and non-infectious]

Table of HIV drug classes and their mechanisms of action
Table 1. The different HIV drug classes and their corresponding mechanism of action are shown

For each antiretroviral class, there are multiple drugs that have been developed over the last 30 years. Newer HIV drugs are more effective, safer and resistant to mutations.

But developing drugs is not always about effectiveness and tolerability, but also about making life easier for patients.

In the past, patients had to take multiple HIV pills each day, but now we have entered the stage where we have single tablet regimens or STRs.

STRs contain multiple HIV drug classes within a single pill, meaning that patients only have to take one tablet, once daily.

The simplicity of taking STRs have been shown to boost adherence in HIV patients, something which is critical in reduce the risk of HIV transmission and the emergence of viral mutations.

With the wide range of effective, safe and simple HIV medications that are available, we have the means to eliminate AIDS within this century.

Related work: how HIV attacks the immune system. NEO MedComms turns complex science like this into clear medical education materials and pharmaceutical communications. Discuss a similar project with our team.

Struggling to make your medical communications stand out?

✕

Hager El-Kaddar

Medical Writer

Hager El-Kaddar is a pharmacist and medical writer specialising in metabolic disease, with expertise that bridges pharmaceutical sciences and extensive experience in medical communications.

Certified under the ABPI Code of Practice, she excels in evidence-based content development, translating complex clinical data into actionable insights while ensuring scientific rigor and ethical compliance.

✕

Mariem Omran

Business Development

Mariem Omran leads Business Development at NEO Medical Communications, building relationships with new partners across the healthcare and life sciences sector.

She takes the time to understand each organisation’s needs and shows how NEO’s scientific and creative teams can help them communicate with clarity and impact.

✕

Sam Madders

Studio Lead

Sam Madders is Studio Lead at NEO Medical Communications, overseeing the production of our design and digital work.

He manages the studio’s workflow and quality standards, making sure every deliverable, from print materials to interactive content, is carefully crafted and delivered to brief.

✕

Jeremiah Eze

Account Executive

Jeremiah Eze is an Account Executive at NEO Medical Communications, supporting clients and project teams day to day.

He coordinates timelines, feedback and deliverables, making sure every project runs smoothly and that clients always know where their work stands.

✕

Homer Jiassemides

Creative Lead

Homer Jiassemides is Creative Lead at NEO Medical Communications, guiding the visual and conceptual direction of our work.

He brings together design, storytelling and scientific accuracy to create campaigns, materials and experiences that capture attention and communicate complex science clearly.

✕

Lorena Torres

Client Services Director

Lorena Torres is a Client Services Director at NEO Medical Communications, where she partners with pharmaceutical, biotech and healthcare clients to turn their objectives into clear, well-managed projects.

She keeps teams aligned from first brief to final delivery, combining a strong understanding of medical communications with a focus on quality, timelines and lasting client relationships.

✕

Nader Qarini

Operations Director

Nader manages the operational infrastructure that keeps projects moving and teams supported. From internal workflows to delivery timelines, he ensures that the right systems are in place to help NEO run smoothly behind the scenes.

✕

Dr. Patrick Blaise Collins

Medical Communications Director

Dr. Patrick Blaise Collins brings over 15 years of experience in medical writing, scientific leadership, and AI-integrated communication, with a PhD in Exercise Physiology and a background in translational research.

He leads NEO’s scientific storytelling with clarity and precision, building strategic content frameworks, and driving innovation across regulated medical environments.

✕

Renisa Desouza

Strategy Director

Renisa Desouza is NEO’s Strategy Director, assisting clients throughout the Americas with strategic direction that’s clear, actionable, and grounded in medical insight.

She works fractionally with commercial and medical teams to shape messaging, streamline execution, and ensure every asset aligns with brand and market goals.

✕

Zoe Phillips

Head of Strategy

Zoe Phillips is Head of Strategy at NEO Medical Communications, leading the thinking behind our clients’ communication plans.

She works closely with clients and the wider NEO team to understand each audience, define the key messages and build strategies that connect scientific evidence with real-world impact.

✕

Arun Dhillon

Client Services Director

Arun acts as the link between clients and internal teams, ensuring that each project starts with a clear understanding of goals and ends with a result that delivers real value.

With experience managing communication across multiple industries, Arun keeps the focus on clarity, timelines, and trust.